Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “formulation”

865 pharma patents match "formulation" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 865
Index total 30,257
Page 6 / 37

Quick answer

This filtered view shows 865 pharmaceutical patents matching "formulation" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

865 results for “formulation” · 30,257 patents in full index Clear search

  1. US 11957740

    Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency

    Prime Bio, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  2. US 11957674

    Formulations of a somatostatin modulator

    CRINETICS PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  3. US 11957754

    Clinical formulations

    Astellas Institute for Regenerative Medicine · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  4. US 11951100

    Formulations of RBP4 inhibitors and methods of use

    Belite Bio, Inc · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  5. US 11952600

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  6. US 11938177

    Peptide vaccine formulations and use thereof for inducing an immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  7. US 11939346

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    Compass Pathfinder Limited · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  8. US 11931328

    Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives

    AMNEAL PHARMACEUTICALS LLC · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  9. US 11931421

    Muscle targeting complexes and formulations for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  10. US 11931354

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  11. US 11926670

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  12. US 11925626

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Corcept Therapeutics Incorporated · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  13. US 11904046

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  14. US 11903920

    Cannabinoid formulation: production method and use

    CHIROSYN DISCOVERY TECHNOLOGIES INC. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  15. US 11878074

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  16. US 11865179

    Progesterone formulations having a desirable PK profile

    Compass Therapeutics LLC · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  17. US 11866743

    Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules

    TELEDYNE FLIR DETECTION, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  18. US 11850225

    Baclofen formulations and methods of minimizing patient exposure to metabolite variations

    AMNEAL PHARMACEUTICALS LLC · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  19. US 11851451

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    Compass Pathfinder Limited · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  20. US 11844779

    PKC-Delta-I inhibitor formulations and uses thereof

    United States Government as represented by the Department of Veterans Affairs · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  21. US 11844805

    Formulations of testosterone and methods of treatment therewith

    The Board of Regents of the University of Texas System · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  22. US 11839594

    Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

    TONIX PHARMA LIMITED · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  23. US 11839623

    Antiviral prodrugs and formulations thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  24. US 11833157

    Precipitation resistant small molecule drug formulations

    XERIS PHARMACEUTICALS, INC. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted